Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jaguar Animal Health ( (JAGX) ) has shared an announcement.
On December 8, 2025, Jaguar Health held a Special Meeting where stockholders approved three proposals, including the issuance of new shares and potential meeting adjournments. The company also announced promising initial results from a trial of crofelemer for infants with microvillus inclusion disease, highlighting its potential to reduce parenteral support needs. This development, alongside a recent FDA meeting, suggests a possible expedited approval pathway, impacting Jaguar’s market positioning and stakeholder interests.
The most recent analyst rating on (JAGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
Jaguar Animal Health’s overall stock score is primarily impacted by its poor financial performance, characterized by high leverage and consistent losses. While there is some positive sentiment from recent earnings and clinical advancements, the technical indicators and valuation metrics remain weak, contributing to a low overall score.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Jaguar Health, Inc. is a commercial stage pharmaceuticals company that develops novel proprietary prescription medicines derived from plants in rainforest areas, focusing on gastrointestinal distress in humans and animals. The company operates through its subsidiaries, including Napo Pharmaceuticals, which develops human prescription pharmaceuticals for neglected gastrointestinal symptoms, and Napo Therapeutics, which expands access to crofelemer in Europe for orphan diseases. Jaguar also has a joint venture, Magdalena Biosciences, focusing on mental health indications.
Average Trading Volume: 178,442
Technical Sentiment Signal: Sell
Current Market Cap: $4.03M
Find detailed analytics on JAGX stock on TipRanks’ Stock Analysis page.